Last reviewed · How we verify
PTX-COVID19-B
PTX-COVID19-B is an mRNA vaccine that encodes viral proteins to stimulate immune responses against SARS-CoV-2.
PTX-COVID19-B is an mRNA vaccine that encodes viral proteins to stimulate immune responses against SARS-CoV-2. Used for COVID-19 prevention.
At a glance
| Generic name | PTX-COVID19-B |
|---|---|
| Sponsor | Providence Therapeutics Holdings Inc. |
| Drug class | mRNA vaccine |
| Target | SARS-CoV-2 spike protein and additional viral antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine delivers lipid nanoparticle-formulated mRNA encoding coronavirus spike and other viral antigens, which are translated by host cells to generate immune recognition. This triggers both cellular and humoral immune responses to prevent or reduce severity of COVID-19 infection.
Approved indications
- COVID-19 prevention
Common side effects
- Injection site pain
- Fatigue
- Headache
- Myalgia
- Fever
Key clinical trials
- PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine. (PHASE2)
- Booster Superiority Study of PTX-COVID19-B Compared to Vaxzevria® in Adults Aged 18 Years and Older (PHASE3)
- Booster Study of PTX-COVID19-B in Adults Aged 18 Years and Older (PHASE3)
- PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |